SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
The Diabetes Educator
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Navaneethan, S. D.
Right arrow Articles by Strippoli, G. F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Navaneethan, S. D.
Right arrow Articles by Strippoli, G. F. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

FEATURES

Antihypertensive Agents in Patients With Diabetes

Trade-off Between Renal and Cardiovascular Protection

Sankar D. Navaneethan, MD, MPH, Marialuisa Querques, MD, Carmen Bonifati, MD and Giovanni F. M. Strippoli, MD, MPH (Hons), MM (Epi)

From the Division of Nephrology, University of Rochester, Rochester, New York (Dr Navaneethan); University of Milan San Raffaele, Milan, Italy (Dr Querues); Department of Emergency and Organ Transplantation, University of Bari, Italy (Dr Bonifati); and the Centre for Kidney Research, Cochrane Renal Group, University of Sydney, Australia (Dr Strippoli).

Correspondence to Sankar D. Navaneethan, MD, MPH, Division of Nephrology, University of Rochester, 601 Elmwood Drive, Box 675, Rochester, NY 14642 (sankardass{at}hotmail.com and gfmstrippoli{at}alice.it).

Purpose

Management of hypertension in patients with diabetes should address both renal and cardiovascular protection. The use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) for control of hypertension in patients with diabetic nephropathy is widely advocated by various international guidelines. Use of any agent that provides tight control of blood pressure is indicated in patients with diabetes but without nephropathy.

Methods

In this article, the authors present a clinical case scenario and review current clinical evidence supporting the use of ACE inhibitors and ARBs in patients with diabetic nephropathy. In addition, the use of ACE and ARBs in patients with diabetes but without nephropathy will be discussed.

Results

Available trial evidence confirms the survival benefits of patients taking ACE inhibitors with diabetic nephropathy. However, the efficacy of ARB inhibitors on survival is unknown. In patients with diabetes without nephropathy, only ACE inhibitors have been found to reduce the risk of onset of microalbuminuria, while all agents affect survival provided a tight control of blood pressure is monitored.

Conclusions

Dose of ACE inhibitors should be titrated appropriately to obtain proven benefits. In summary, current evidence supports the use of ACE inhibitors in patients with and without nephropathy because of renal and cardiovascular benefits.

The Diabetes Educator, Vol. 32, No. 4, 596-602 (2006)
DOI: 10.1177/0145721706290835
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




Advertisement